Chiome BioscienceChiome Bioscience Inc.4583東証グロース医薬品FY ending Dec 2025, non-consolidated, J-GAAP

Chiome Bioscience FY ending Dec 2019 results

About 93% of Chiome Bioscience's sales come from Drug Discovery Support, with Drug Discovery and Development making up much of the rest.

It lost about ¥313 for every ¥100 of sales at the operating level.

Where the money goes

For every ¥100 Chiome Bioscience sells, how much goes where, and how much is kept.

FY ending Dec 2019

Margin funnel (derived from reported values)Gross margin 63.6% → Operating margin -313.2% → Net margin -313.6%

Revenue by business segment, and the profit each one keeps.

FY ending Dec 2019

Drug Discovery Support¥417.7M
93%
Op. margin 61.3%Industry: CRO & Clinical Testing
Drug Discovery and Development¥29.9M
7%
Op. margin -4246.8%Industry: Biotech & Regenerative Medicine

※ Segment figures include inter-segment sales and do not sum to the company total

Show source documents (3)

EDINET (FSA Japan)
訂正有価証券報告書－第20期(2023/01/01－2023/12/31)
ID S100USPT2024-11-15Open
EDINET (FSA Japan)
有価証券報告書－第18期(令和3年1月1日－令和3年12月31日)
ID S100NQ6T2022-03-25Open
EDINET (FSA Japan)
有価証券報告書－第17期(令和2年1月1日－令和2年12月31日)
ID S100L1372021-03-26Open

Extracted from XBRL: 34

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.